MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.17 -6.4

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.15

Max

1.25

Põhinäitajad
By Trading Economics
Sissetulek	-4.5M -52M
Müük	-1.2M 1.9M
Aktsiakasum	-0.44
Kasumimarginaal	-2,803.925
Töötajad	181
EBITDA	10M -42M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+393.6% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	8. mai 2025

Turustatistika
By TradingEconomics
Turukapital	34M 151M
Eelmine avamishind	7.57
Eelmine sulgemishind	1.17

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

1.1 / 1.35 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2025, 23:53 UTC

Kuumad aktsiad

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29. apr 2025, 23:06 UTC

Tulu

Prudential PLC 1Q New Business Profit Increases by 12%

29. apr 2025, 23:00 UTC

Tulu

America Movil's Posts Rise in 1Q Profit, Revenue

30. apr 2025, 00:00 UTC

Peamised uudised

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29. apr 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29. apr 2025, 23:41 UTC

Tulu

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29. apr 2025, 23:24 UTC

Tulu

China Vanke 1Q Loss Widened Significantly >000002.SZ

29. apr 2025, 23:15 UTC

Peamised uudised

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29. apr 2025, 23:14 UTC

Tulu

China Eastern Airlines 1Q Loss Widened >0670.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines Swung to Loss in 1Q>1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29. apr 2025, 23:11 UTC

Tulu

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Losses Widened>0753.HK

29. apr 2025, 23:07 UTC

Tulu

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29. apr 2025, 23:02 UTC

Tulu

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

393.6% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD 393.6%

Kõrge 12 USD

Madal 2.5 USD

Põhineb 12 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.1 / 1.35Toetus ja vastupanu

Recent bullish events outweigh bearish events.

All events are bullish.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.